Literature DB >> 16003551

Oropharyngeal carcinoma and its treatment in Finland between 1995-1999: a nationwide study.

Antti A Mäkitie1, Matti Pukkila, Jussi Laranne, Jaakko Pulkkinen, Jyrki Vuola, Leif Bäck, Petri Koivunen, Reidar Grénman.   

Abstract

The survival figures for advanced stage oropharyngeal carcinoma (OPC) have remained moderate in spite of radical combined modality treatments. The purpose of this study was to investigate the used treatment approach and the outcome of OPC in a nationwide study. Retrospective clinicopathological data of all patients diagnosed with OPC between 1995 and 1999 at the five university hospitals in Finland were reviewed. All patients had a minimum 4-year follow-up. A total of 168 patients (145 men and 23 women, mean age 59 years; range 28 - 89 years) were included. The T categories were as follows: T1, n =34; T2, n =55; T3, n =40; T4, n =39. One hundred and seventeen (69.6%) patients presented with neck node metastases and three (1.8%) patients with distant metastases. In the majority (61.3%) of the patients the tumor was located in the lateral wall of the oropharynx. In 144 (85.7%) patients the treatment was performed with curative intent. Of these, surgery of the primary tumor was performed in 123 (85.4%) patients, and the defect was reconstructed with a pedicled flap or free tissue transfer in 66 (53.7%) of these patients. A neck dissection (ND) was performed in 86 (69.9%) out of these 123 cases. Surgery was the only treatment modality in 10 (6.9%) patients. Radiation therapy (RT) only (with or without chemotherapy) was given to 21 (14.6%), combined treatment with surgery + radiation therapy (S + RT) to 110 (76.4%) and surgery + chemoradiotherapy (S + CRT) to 3 (2.1%) patients. Overall (OS) 3- and 5-year survival rates were 58 and 45%, respectively. Disease-specific (DSS) 5-year survival rates by T-class for the patients treated with curative intent were as follows: T1, 77%; T2, 70%; T3, 66%; T4, 53%. The variable treatment approach, the frequent locoregional recurrences and the moderate survival point out the need to consider new strategies in the management of OPC.

Entities:  

Mesh:

Year:  2005        PMID: 16003551     DOI: 10.1007/s00405-005-0975-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  9 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Primary surgery as treatment for early squamous cell carcinoma of the tonsil.

Authors:  L T Galati; E N Myers; J T Johnson
Journal:  Head Neck       Date:  2000-05       Impact factor: 3.147

4.  Squamous cell carcinoma of the oropharynx--an analysis of treatment results in 289 consecutive patients.

Authors:  L V Johansen; C Grau; J Overgaard
Journal:  Acta Oncol       Date:  2000       Impact factor: 4.089

Review 5.  Cancer of the oropharynx.

Authors:  Lisa Licitra; Jacques Bernier; Cesare Grandi; Marco Merlano; Paolo Bruzzi; Jean-Louis Lefebvre
Journal:  Crit Rev Oncol Hematol       Date:  2002-01       Impact factor: 6.312

6.  Functional status after primary surgical therapy for squamous cell carcinoma of the base of the tongue.

Authors:  Paul Friedlander; Salvatore Caruana; Bhuvanesh Singh; Ashok Shaha; Dennis Kraus; Louis Harrison; Janet McKiernan; Jill Solan; Tatyana Polyak; Jatin P Shah
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

7.  Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.

Authors:  Fabrice Denis; Pascal Garaud; Etienne Bardet; Marc Alfonsi; Christian Sire; Thierry Germain; Philippe Bergerot; Beatrix Rhein; Jacques Tortochaux; Gilles Calais
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

8.  The National Cancer Data Base report on squamous cell carcinoma of the base of tongue.

Authors:  Weining Zhen; Lucy H Karnell; Henry T Hoffman; Gerry F Funk; John M Buatti; Herman R Menck
Journal:  Head Neck       Date:  2004-08       Impact factor: 3.147

9.  Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both.

Authors:  James T Parsons; William M Mendenhall; Scott P Stringer; Robert J Amdur; Russell W Hinerman; Douglas B Villaret; Giselle J Moore-Higgs; Bruce D Greene; Tod W Speer; Nicholas J Cassisi; Rodney R Million
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

  9 in total
  6 in total

1.  Treatment Outcomes and Quality of Life in Oropharyngeal Cancer after Surgery-based versus Radiation-based Treatment.

Authors:  Tae Wook Kim; Hye-Youn Youm; Hayoung Byun; Young-Ik Son; Chung-Hwan Baek
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-09-17       Impact factor: 3.372

2.  Primary surgery results in no survival benefit compared to primary radiation for oropharyngeal cancer patients stratified by high-risk human papilloma virus status.

Authors:  Stein Lybak; Borghild Ljøkjel; Hilde Haave; Àsa Karlsdottir; Olav K Vintermyr; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-04       Impact factor: 2.503

Review 3.  [Combined modality approaches in the treatment of head and neck cancer patients].

Authors:  C Simon; P K Plinkert
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

4.  End-of-life care pathway of head and neck cancer patients: single-institution experience.

Authors:  T Heinonen; V Loimu; K Saarilahti; T Saarto; A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-15       Impact factor: 2.503

5.  Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma.

Authors:  Stein Lybak; Per Gunnar Liavaag; Odd R Monge; Jan Olofsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-08-28       Impact factor: 2.503

6.  Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers.

Authors:  Chameera Ekanayake Weeramange; Zhen Liu; Gunter Hartel; Yinan Li; Sarju Vasani; Julian Langton-Lockton; Lizbeth Kenny; Luc Morris; Ian Frazer; Kai D Tang; Chamindie Punyadeera
Journal:  J Mol Diagn       Date:  2021-07-27       Impact factor: 5.341

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.